同步化放疗治疗局限期小细胞肺癌的中期生存率及安全性

Medium-term survival and safety of concurrent chemoradiotherapy for limited stage small cell lung cancer

目的:观察同步化放疗治疗局限期小细胞肺癌的中期生存率及安全性。方法:抽取河南神火集团职工总医院2014年1月至2015年10月接受治疗的局限期小细胞肺癌患者60例,按照随机数表法分为研究组(30例)与对照组(30例)。对照组接受序贯化放疗(4~6周期化疗后单纯放疗),研究组接受同步化放疗(化疗2周期后,同时进行化疗与放疗),6周期为一疗程,治疗2个疗程后,比较两组治疗效果,记录治疗期间不良反应发生情况。治疗结束后随访3年,记录患者随访1、2、3年生存率。结果:研究组治疗有效率高于对照组,中位生存期长于对照组,随访1、2、3年,生存率高于对照组,差异有统计学意义(P<0.05);治疗期间,两组患不良反应发生率比较差异未见统计学意义(P>0.05)。结论:同步化放疗治疗局限期小细胞肺癌较序贯放化疗能更好控制患者病情,患者中期生存率提高,不良反应未增加。

Objective To observe the mid-term survival rate and safety of concurrent chemoradiotherapy for limited stage small cell lung cancer.Methods Sixty patients with limited stage small cell lung cancer in Henan Shenhuo Group Staff General Hospital from January 2014 to October 2015 were selected and randomly divided into study group(30 cases)and control group(30 cases).The control group received sequential chemoradiotherapy(4-6 cycles of chemotherapy followed by radiotherapy alone),and the study group received synchronous chemoradiotherapy(2 cycles of chemotherapy,chemotherapy and radiotherapy at the same time),6 cycles for a course of treatment.After 2 courses of treatment,the treatment effect of the two groups was compared,the incidence of adverse reactions during the treatment was recorded,and the 1-year,2-year and 3-year survival rates were recorded.Results The effective rate of the study group was higher than that of the control group,and the median-survival time was longer than that of the control group.The 1-year,2-year and 3-year survival rates of the study group were higher than those of the control group(P<0.05);during the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Concurrent chemoradiotherapy for limited stage small cell lung cancer can control the patient’s condition better than sequential radiotherapy and chemotherapy.The medium-term survival rate of patients is significantly improved,and the side effects are not increased.